.jpg?format=webp&width=780)
The purpose of the review was to summarize real‐world efficacy and safety data on brolucizumab in patients with nAMD. The review protocol was registered with PROSPERO. The study conducted systematic searches in Embase, Medline and key ophthalmology congress websites. Original reports of efficacy and/or safety in patients receiving brolucizumab to treat nAMD in clinical practice were eligible. Outcomes were available for treatment‐naive eyes, eyes switched to brolucizumab from other anti‐VEGFs, and/or treatment‐naive and change eyes combined. The incidence of intraocular inflammation ranged from 0% to 19%. In conclusion, real‐world efficacy and safety data concur with brolucizumab pivotal trials.
Like
Save
Share